Logo 1.png
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
January 17, 2023 08:05 ET | Aeterna Zentaris Inc
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across...
Logo 1.png
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
January 10, 2023 08:05 ET | Aeterna Zentaris Inc
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...
Logo 1.png
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
November 03, 2022 08:05 ET | Aeterna Zentaris Inc
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 ...
Logo 1.png
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
August 29, 2022 08:00 ET | Aeterna Zentaris Inc
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal...
Logo 1.png
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
August 03, 2022 17:30 ET | Aeterna Zentaris Inc
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE...
Logo 1.png
Aeterna Zentaris Announces Effective Date of Share Consolidation
July 18, 2022 17:06 ET | Aeterna Zentaris Inc
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Logo 1.png
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
July 15, 2022 16:15 ET | Aeterna Zentaris Inc
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Logo 1.png
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
July 06, 2022 16:05 ET | Aeterna Zentaris Inc
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Logo 1.png
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
June 21, 2022 16:01 ET | Aeterna Zentaris Inc
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
Logo 1.png
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
June 13, 2022 08:00 ET | Aeterna Zentaris Inc
– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th...